Replies to post #190776 on Biotech Values

[DewDiligence]

MNTA +10% on CAFC's invalidating Teva’s ‘808 Copaxone patent (#msg-114705537). NVS/MNTA are now free to lunch Glatopa (generic Copaxone) immediately, barring a stay of the CAFC ruling, which seems unlikely.